Vij R - Search Results

1

Bones in Multiple Myeloma: Imaging and Therapy.

Zamagni E, Cavo M, Fakhri B, Vij R, Roodman D. Zamagni E, et al. Among authors: vij r. Am Soc Clin Oncol Educ Book. 2018 May 23;38:638-646. doi: 10.1200/EDBK_205583. Am Soc Clin Oncol Educ Book. 2018. PMID: 30231385 Free article. Review.

2

Bortezomib inhibits osteoclast activity in patients with multiple myeloma.

Uy GL, Trivedi R, Peles S, Fisher NM, Zhang QJ, Tomasson MH, DiPersio JF, Vij R. Uy GL, et al. Among authors: vij r. Clin Lymphoma Myeloma. 2007 Nov;7(9):587-9. doi: 10.3816/clm.2007.n.045. Clin Lymphoma Myeloma. 2007. PMID: 18186967 Clinical Trial.

3

Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma.

O'Neal J, Gao F, Hassan A, Monahan R, Barrios S, Kilimann MW, Lee I, Chng WJ, Vij R, Tomasson MH. O'Neal J, et al. Among authors: vij r. Exp Hematol. 2009 Feb;37(2):234-44. doi: 10.1016/j.exphem.2008.10.014. Exp Hematol. 2009. PMID: 19135901 Free PMC article.

4

An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma.

Vij R, Horvath N, Spencer A, Taylor K, Vadhan-Raj S, Vescio R, Smith J, Qian Y, Yeh H, Jun S. Vij R, et al. Am J Hematol. 2009 Oct;84(10):650-6. doi: 10.1002/ajh.21509. Am J Hematol. 2009. PMID: 19714603 Free article. Clinical Trial.

5

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S. Lonial S, et al. Among authors: vij r. J Clin Oncol. 2012 Jun 1;30(16):1953-9. doi: 10.1200/JCO.2011.37.2649. Epub 2012 Apr 30. J Clin Oncol. 2012. PMID: 22547589 Clinical Trial.

6

Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress.

Chu L, Su MY, Maggi LB Jr, Lu L, Mullins C, Crosby S, Huang G, Chng WJ, Vij R, Tomasson MH. Chu L, et al. Among authors: vij r. J Clin Invest. 2012 Aug;122(8):2793-806. doi: 10.1172/JCI63051. Epub 2012 Jul 2. J Clin Invest. 2012. PMID: 22751105 Free PMC article.

7

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN. Hurchla MA, et al. Among authors: vij r. Leukemia. 2013 Feb;27(2):430-40. doi: 10.1038/leu.2012.183. Epub 2012 Jul 5. Leukemia. 2013. PMID: 22763387 Free PMC article.

8

Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myeloma.

Hucthagowder V, Meyer R, Mullins C, Nagarajan R, DiPersio JF, Vij R, Tomasson MH, Kulkarni S. Hucthagowder V, et al. Among authors: vij r. Cancer Genet. 2012 Sep;205(9):474-8. doi: 10.1016/j.cancergen.2012.06.007. Cancer Genet. 2012. PMID: 22939401 Free PMC article.

9

Carfilzomib in multiple myeloma.

Vij R. Vij R. Clin Adv Hematol Oncol. 2012 Sep;10(9):591-3. Clin Adv Hematol Oncol. 2012. PMID: 23073124 No abstract available.

10

Influence of body mass index on survival in veterans with multiple myeloma.

Beason TS, Chang SH, Sanfilippo KM, Luo S, Colditz GA, Vij R, Tomasson MH, Dipersio JF, Stockerl-Goldstein K, Ganti A, Wildes T, Carson KR. Beason TS, et al. Among authors: vij r. Oncologist. 2013;18(10):1074-9. doi: 10.1634/theoncologist.2013-0015. Epub 2013 Sep 18. Oncologist. 2013. PMID: 24048366 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

452 results

Search Page

Filters